🗞️ IMPROVE-2 Study News!
DiCE met with the research team at #ESMO2024 to discuss the study on intermittent Panitumumab + FOLFIRI for colorectal cancer. This approach may reduce side effects and personalise treatment.
Stay tuned for more! 💪
It's #KidneyCancerAwarenessWeek! 🌍
Enhancing #mRCC Treatment with #FecalMicrobiotaTransplantation 🎥 🗞️
Dr. Chiara Ciccarese, Fondazione Policlinico Universitario A. Gemelli IRCCS, discusses findings from the Phase II TACITO trial (NCT04758507) 🔦
👉 https://buff.ly/42nVXnT
#ESMO2024 #mRCC
#KidneyCancerAwarenessWeek 🌍 🗞️
Dr. Ignacio Duran, Hospital Universitario Marques de Valdecilla, shares insights from key #kidneycancer studies presented at the ESMO 2024 Congress💡🎥
👉 https://buff.ly/42gQE9Y
#ESMO2024 #KidneyCancerResearch #OncologyUpdates #CheckpointInhibitors
Alphamab Oncology Has Received Approval for JSKN033 Clinical Trial
oncodaily.com/insight/alph...
#Alphamab #Oncology #Cancer #ESMO2024 #OncoDaily #Oncology #Medicine #Health
The phase III KEYNOTE-867 study results at ESMO 2024 - Drew Moghanaki
oncodaily.com/blog/drew-mo...
@drewmoghanaki.bsky.social
#Cancer #ESMO #ESMO2024 #OncoDaily #Oncology
NEW PODCAST: The latest episode of The Oncology Journal Club Podcast just dropped!
Thanks to my co hosts @drkiwikate.bsky.social and Prof Chris Jackson
Listen here: t.ly/ERBmn, Spotify etc
#ojc #ESMO2024 #oncsky #medsky
... and the SunRise 2 and 4 (TAR-200) results of high T0 response rates reports suggest changes to care. Neither yet published, but shown at #ESMO2024. See www.youtube.com/watch?v=HZK4... and www.targetedonc.com/view/sunrise...
Prof Susie Banerjee presented the SOPRANO 'Trials in Progress' poster at #ESMO2024 last weekend. The trial is investigating whether stereotactic body #radiotherapy on its own or with the drug, niraparib, works better to prevent certain types of ovarian cancer from getting worse.
Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
On the other hand, the number of possible lives saved from improved allocation of resources is encouraging. Not everything in cancer care is expensive. #esmo2024
This development worries me quite a bit. Progress that gets more and more costly, but still continues forward, is a hard problem to solve. #esmo2024
Join us at #ESMO2024 where Exai will present new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer
ESMO Congress 2024 count-down. 5 days 22 hours until this years event opens in Barcelona… Contact me to talk about U.K. cancer research, funding, EDI and culture.
Who will be at #ESMO2024?
Aiming to meet lots of UK-based cancer researchers at scientific sessions, YO series & posters. Do reach out to arrange a convo!
#cancerresearch #researchcareers #discoveryresearch #clinicaltrials #researchtranslation #oncology #clinicalimplementation #cancer
